Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | TSHR | P16473 | 3/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | POLQ | O75417 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 6/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28989466 | 0.83 | LMNA (0.48) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL15708270 | 0.82 | TRPM2 (0.43) | LMNATSHRNPSR1GAATDP1 | |
| SCHEMBL18853767 | 0.79 | LMNA (0.36) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL20079046 | 0.79 | LMNA (0.38) | LMNATSHRNPSR1ALDH1A1 | |
| SCHEMBL15708216 | 0.77 | LMNA (0.58) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL14487956 | 0.76 | TRPM2 (0.46) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL24088583 | 0.76 | LMNA (0.50) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL19890880 | 0.76 | LMNA (0.50) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL24165329 | 0.76 | LMNA (0.50) | LMNATSHRNPSR1GAAALDH1A1 | |
| SCHEMBL15708958 | 0.74 | LMNA (0.62) | LMNATSHRNPSR1GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4092020-B1 | SOLID FORMS OF AN HIV CAPSID INHIBITOR | GILEAD SCIENCES INC (US) | 2024-07-10 | — | — | EP | disclosed |
| EP-3954679-A2 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2022-02-16 | — | — | EP | disclosed |
| EP-3409667-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV INFECTIONS | GILEAD SCIENCES INC (US) | 2021-07-21 | — | — | EP | disclosed |
| WO-2021104413-A1 | FUSED PYRIDINE RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2021-06-03 | — | — | WO | disclosed |
| US-20200262815-A1 | THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. | 2020-08-20 | — | — | US | disclosed |
| WO-2019035973-A1 | CHOLINE SALT FORMS OF AN HIV CAPSID INHIBITOR | GILEAD SCIENCES, INC (US) | 2019-02-21 | — | — | WO | disclosed |
| EP-2961742-B1 | AMIDE COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2018-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200262815-A1 | THERAPEUTIC COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | LMNA 4352/4885TSHR 4787/4885NPSR1 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.